Potential discontinuation of tofacitinib following the achievement of LDA (low disease activity) in patients with rheumatoid arthritis.

Trial Profile

Potential discontinuation of tofacitinib following the achievement of LDA (low disease activity) in patients with rheumatoid arthritis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Apr 2017 New trial record
    • 12 Apr 2017 Results published in the Rheumatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top